Can I read Rilpivirine inhibits SARS-CoV-2 protein targets: A potential multi-target drug on EtoBox?
Rilpivirine inhibits SARS-CoV-2 protein targets: A potential multi-target drug by Fuad Ameen; Estari Mamidala; Rakesh Davella; Shravan Vallala is a Medicine article available to read on EtoBox.
What is Rilpivirine inhibits SARS-CoV-2 protein targets: A potential multi-target drug about?
## Background: Covid-19 disease caused by sars-cov-2 is lacking efficient medication although certain medications are used to relief its symptoms. ## Objectives: We tested an fda-approved antiviral medication namely rilpivirine to find a drug against sars-cov-2. ## Methods: The inhibition of rilpivirine against multiple sars-cov-2 therapeutic targets was studied using in silico method. the binding attraction of the protein-ligand complexes were calculated using molecular docking analysis. ## Results: Docking rilpivirine with main protease (mpro), papin like protease (plpro), sprike protein (spro), human angiotensin converting enzyme-2 (ace2), and rna dependent-rna polymerase (rdrp) yielded binding energies of -8.07, -8.40, -7.55, -9.11, and -8.69 kcal/mol, respectively. the electrostatic interaction is the key force in stabilizing the rdrp-rilpivirine complex, while van der waals interaction dominates in the ace2 rilpivirine case. our findings suggest that rilpivirine can inhibit sars-cov-2 replication by targeting not only ace2, but also rdrp and other targets, and therefore, it can be used to invoke altered mechanisms at the pre-entry and post-entry phases. ## Conclusion: As a re
Who reads Rilpivirine inhibits SARS-CoV-2 protein targets: A potential multi-target drug?
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- Fuad Ameen; Estari Mamidala; Rakesh Davella; Shravan Vallala
- Publisher
- Elsevier BV
- Published
- 2021
- Language
- EN
- Field
- Medicine (Health Sciences)